AstraZeneca to Buy Icosavax for Up to 1.1 Bln
| ICVXDelisted Stock | USD 9.02 0.12 1.31% |
Slightly above 62% of Icosavax's investor base is looking to short. The analysis of current outlook of investing in Icosavax suggests that many traders are alarmed regarding Icosavax's prospects. Icosavax's investing sentiment can be driven by a variety of factors including economic data, Icosavax's earnings reports, geopolitical events, and overall market trends.
Icosavax |
By Ian Walker AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to 1.1 billion in a deal that expands its...
Read at marketwatch.com
 |
Icosavax Fundamental Analysis
We analyze Icosavax's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Icosavax using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Icosavax based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Icosavax is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Icosavax Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Icosavax stock to make a market-neutral strategy. Peer analysis of Icosavax could also be used in its relative valuation, which is a method of valuing Icosavax by comparing valuation metrics with similar companies.
Peers
Icosavax Related Equities
| XFOR | X4 Pharmaceuticals | 11.43 | ||||
| ELDN | Eledon Pharmaceuticals | 9.39 | ||||
| IMMX | Immix Biopharma | 7.11 | ||||
| HEPA | Hepion Pharmaceuticals | 4.69 | ||||
| PDSB | PDS Biotechnology | 1.86 | ||||
| HOOK | Hookipa Pharma | 1.61 | ||||
| DAWN | Day One | 1.53 | ||||
| MREO | Mereo BioPharma | 1.40 | ||||
| ABOS | Acumen Pharmaceuticals | 0.44 | ||||
| INZY | Inozyme Pharma | 0.37 | ||||
| TERN | Terns Pharmaceuticals | 1.58 | ||||
| AMLX | Amylyx Pharmaceuticals | 3.48 | ||||
| CNSP | Cns Pharmaceuticals | 8.33 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in Icosavax Stock
If you are still planning to invest in Icosavax check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Icosavax's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |